While scientific innovation accelerates, patient access continues to lag. This is not due to limited discovery, but to fragmented patient engagement across the product lifecycle.
This report explores why traditional models of patient centricity fall short and makes the case for a unified Chief Patient Officer (CPO) capability to align evidence generation, access strategy, and system readiness.
Drawing on real-world case studies and evolving HTA and regulatory expectations, it outlines how leading life sciences organizations can translate patient insights into measurable clinical and commercial impact.
